343 related articles for article (PubMed ID: 29896926)
1. Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer.
Tanaka M; Hoashi T; Ichiyama S; Noro R; Seike M; Kubota K; Gemma A; Funasaka Y; Saeki H
Australas J Dermatol; 2019 Feb; 60(1):e67-e68. PubMed ID: 29896926
[No Abstract] [Full Text] [Related]
2. Histologically-diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report.
Kim YE; Kim TM; Jo SJ
J Dermatol; 2019 Dec; 46(12):e464-e466. PubMed ID: 31531885
[No Abstract] [Full Text] [Related]
3. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
Callens R; Tamsin A; van Zandweghe L
J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
[No Abstract] [Full Text] [Related]
4. Generalized Lichen Nitidus Following Anti-PD-1 Antibody Treatment.
Cho M; Nonomura Y; Kaku Y; Dainichi T; Otsuka A; Kabashima K
JAMA Dermatol; 2018 Mar; 154(3):367-369. PubMed ID: 29344609
[No Abstract] [Full Text] [Related]
5. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
[No Abstract] [Full Text] [Related]
6. Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.
Kato R; Hayashi H; Sano K; Handa K; Kumode T; Ueda H; Okuno T; Kawakami H; Matsumura I; Kudo M; Nakagawa K
J Thorac Oncol; 2018 Dec; 13(12):e239-e241. PubMed ID: 30017828
[No Abstract] [Full Text] [Related]
7. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
8. New onset of psoriasis during nivolumab treatment for lung cancer.
Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
[No Abstract] [Full Text] [Related]
9. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
10. Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
Guaitoli G; Baldessari C; Tomasello C; Barbieri F; Cascinu S; Bertolini F; Cesinaro AM
J Thorac Oncol; 2018 Aug; 13(8):e152-e153. PubMed ID: 30049380
[No Abstract] [Full Text] [Related]
11. Asteatotic eczema ('eczema craquelé') with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed.
Frouin E; Sebille G; Freudenberger S; Menecier B; Quoix E; Cribier B; Lipsker D
Br J Dermatol; 2012 Jun; 166(6):1359-60. PubMed ID: 22182200
[No Abstract] [Full Text] [Related]
12. Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy.
Matsumoto Y; Kadono T; Matsuoka M; Kawakami T; Furuya N; Doi M; Hoshikawa M; Soma Y
J Dermatol; 2018 Feb; 45(2):e33-e34. PubMed ID: 28984022
[No Abstract] [Full Text] [Related]
13. Bilateral Anterior Uveitis Associated with Nivolumab Therapy.
Karlin J; Gentzler R; Golen J
Ocul Immunol Inflamm; 2018; 26(2):283-285. PubMed ID: 27599197
[No Abstract] [Full Text] [Related]
14. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
Bednarek R; Marks K; Lin G
Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
[No Abstract] [Full Text] [Related]
15. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
[No Abstract] [Full Text] [Related]
16. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
17. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
[No Abstract] [Full Text] [Related]
18. Acute demyelinating polyneuropathy induced by nivolumab.
Fukumoto Y; Kuwahara M; Kawai S; Nakahama K; Kusunoki S
J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):435-437. PubMed ID: 28844069
[No Abstract] [Full Text] [Related]
19. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
Schouten RD; Muller M; de Gooijer CJ; Baas P; van den Heuvel M
Lung Cancer; 2018 Dec; 126():210-216. PubMed ID: 29179916
[No Abstract] [Full Text] [Related]
20. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
